庞宝莹 匡洪宇

    [摘要] 非酒精性脂肪性肝病(NAFLD)是世界范围内最普遍的慢性肝病，2型糖尿病与之密切相关。目前，生活方式干预是治疗NAFLD的主要方法。肠促胰素类药物包括胰高血糖素样多肽-1受体激动剂和二肽基肽酶-4抑制剂，这是两种使用最广泛的新型降糖药物。大量的临床试验研究评估了肠促胰素类药物对肝脏脂肪含量的影响，肠促胰素类药物可能是NAFLD治疗的新选择。本文对近年肠促胰素类药物治疗NAFLD的相关临床试验研究作一综述。

    [关键词] 非酒精性脂肪性肝病；肠促胰素；胰高血糖素样多肽-1；二肽基肽酶-4；肝脏脂肪含量

    [中图分类号] R575 [文献标识码] A [文章编号] 1673-7210(2018)02(c)-0028-04

    [Abstract] Type 2 diabetes mellitus is closely associated with non-alcoholic fatty liver disease (NAFLD)， which is the most prevalent chronic liver disease worldwide. Currently， the only validated treatment for NAFLD is lifestyle intervention. Glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors， collectively termed incretin-based therapies， represent two of the most widely used classes of novel antidiabetic drugs. A number of studies of human trials have evaluated the effects of incretins on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this paper， the main clinical studies regarding the effects of incretins on NAFLD are reviewed.

    [Key words] Nonalcoholic fatty liver disease； Incretins； Glucagon-like peptide-1； Dipeptidy peptidase-4； Liver fat content ......